Sunday, August 17, 2025 8/17/2025

Whole body single AAV microgene in canine DMD

Award Number: R01NS090634
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2015
PERIOD OF PERFORMANCE END DATE: 04/30/2030

Group Awards By:

View Award Description

Whole body single AAV microgene in canine DMD - Project Description Duchenne muscular dystrophy (DMD) is a lethal X-linked muscle-wasting disease caused by dystrophin deficiency. Adeno-associated virus (AAV)-mediated systemic microdystrophin (μDys) gene therapy aims to treat DMD with a bodywide expression of abbreviated dystrophin. With the support from NIH, we have made many important contributions to the development of AAV μDys gene therapy. We pioneered AAV μDys therapy for DMD cardiomyopathy; we were among the first to show that AAV μDys therapy can improve muscle force in the mouse model; we were the first to demonstrate the histological and physiological benefits of AAV μDys therapy in a large dystrophic mammal (the canine DMD model) by intramuscular injection; and we were the first to achieve successful bodywide AAV μDys therapy in the canine DMD model. In addition, we discovered several domains important for μDys function, including the dystrophin nNOS-binding domain and membrane-binding domains. These studies and the outstanding contributions from many other laboratories have led to systemic AAV μDys trials in DMD patients by several biopharma companies and the recent approval of an AAV μDys drug by the FDA. Despite encouraging progress, several important issues surfaced in clinical trials. These include toxicity associated with high-dose systemic AAV delivery, low efficacy and immunogenicity of current μDys constructs, and uncertainty of the longevity of the therapy. The field is also hindered by the lack of a good method for predicting AAV performance in human muscle. The canine model is the most established large animal model. It faithfully recapitulates human disease. We are a world-leading laboratory developing DMD gene therapy in the canine model. We recently developed a xenograft model for testing systemic AAV delivery in human muscle. In this renewal, we will leverage our expertise in AAV μDys therapy, the canine DMD model, and the human muscle xenograft model to (1) address whether the toxicity associated with the high-dose AAV administration can be attenuated with the newly developed more potent myotropic AAV capsids; (2) determine whether myotropic AAV μDys therapy can result in long-term therapeutic benefits in the canine DMD model; (3) identify the best-performing AAV capsids for systemic gene therapy in human muscle, and (4) develop more potent, deimmunized next-generation μDys constructs. Our studies will greatly advance AAV μDys gene therapy for DMD and reduce the disease burden on patients, families, and society.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $598,651 )
2025	2025	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	6	6/27/2025	COMPETING CONTINUATION	$598,651
														Subtotal = $598,651

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2019	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	3/5/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	8/26/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	9/14/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $600,331 )
2019	2019	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	7/16/2019	NON-COMPETING CONTINUATION	$600,331
														Subtotal = $600,331

Issue Date FY: 2018 ( Subtotal = $600,331 )
2018	2018	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	7/26/2018	NON-COMPETING CONTINUATION	$600,331
														Subtotal = $600,331

Issue Date FY: 2017 ( Subtotal = $600,331 )
2017	2017	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	7/27/2017	NON-COMPETING CONTINUATION	$600,331
														Subtotal = $600,331

Issue Date FY: 2016 ( Subtotal = $600,331 )
2016	2016	CURATORS OF THE UNIVERSITY OF MISSOURI	5100 Rockhill Road	Kansas City	MO	64110	JACKSON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	8/2/2016	NON-COMPETING CONTINUATION	$600,331
														Subtotal = $600,331

Issue Date FY: 2015 ( Subtotal = $600,331 )
2015	2015	CURATORS OF THE UNIVERSITY OF MISSOURI	5100 Rockhill Road	Kansas City	MO	64110	JACKSON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	8/28/2015	NEW	$600,331
														Subtotal = $600,331

Grand Total All Awards = $3,600,306

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Whole body single AAV microgene in canine DMD

Award Number: R01NS090634

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2015

PERIOD OF PERFORMANCE END DATE: 04/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer